Aggrenox Journal Ad Improperly Suggests Superiority To Plavix, FDA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The paper referenced in the ad is "a historically controlled trial that is inadequate to support a superiority claim," the FDA ad division letter states. The agency also cites the Aggrenox ad for omitting risk information.
You may also be interested in...
Crestor Campaign Makes FDA Complain; "Clearly The Best" Given A Rest
An FDA "untitled" letter takes issue with AstraZeneca's presentation of comparative claims to other statins in an ad campaign that states Crestor is "clearly the best." This is the second ad division letter sent to AstraZeneca for Crestor promotions. AstraZeneca says the FDA-cited campaign concluded at the end of 2004.
DTC Ad Comparative Claims Draw FDA Criticism, Even With “Scientific Basis”
“We’re not pleased with the way direct-to-consumer advertising is going,” Acting Commissioner Crawford says. DTC ads have become “ridiculous,” he says; “very strong measures” by FDA may be warranted.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.